T. Hensing

发表

Gianguido C. Cianci, M. Vannier, Chin-Tu Chen, 2015, Nature Reviews Clinical Oncology.

Utilisation of a thoracic oncology database to capture radiological and pathological images for evaluation of response to chemotherapy in patients with malignant pleural mesothelioma

S. Armato, A. Starkey, R. Salgia, 2012, BMJ Open.

Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

R. Schilsky, T. Hensing, P. Ganz, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research

R. Salgia, T. Hensing, R. Hasina, 2011, Journal of visualized experiments : JoVE.

Molecular biomarkers for future screening of lung cancer

Ravi Salgia, R. Salgia, T. Hensing, 2013, Journal of surgical oncology.

Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial.

M. Socinski, F. Detterbeck, T. Hensing, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Promotion of self-management for post treatment cancer survivors: evaluation of a risk-adapted visit

D. Merkel, T. Hensing, J. Obel, 2016, Journal of Cancer Survivorship.

KRAS in Non-Small-Cell Lung Cancer-Reply.

R. Salgia, T. Hensing, Kevin Wood, 2016, JAMA oncology.

Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer

M. Socinski, N. Hanna, T. Hensing, 2006, Anti-cancer drugs.

Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy.

M. Lacouture, T. Hensing, M. Mulcahy, 2010, Journal of the National Cancer Institute.

Cancer esearch rated Systems and Technologies ical Detection of Buccal Epithelial Nanoarchitectural rations in Patients Harboring Lung Cancer : R lications for Screening nt

V. Backman, W. Rom, T. Hensing, 2010 .

Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer.

M. Socinski, C. Poole, F. Detterbeck, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationship between symptom change, objective tumor measurements, and performance status during chemotherapy for advanced lung cancer.

B. Parasuraman, D. Cella, D. Eton, 2008, Clinical lung cancer.

Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program.

R. Govindan, R. Herbst, K. Kelly, 2006, Lung cancer.

Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.

A. Rademaker, E. Hart, T. Hensing, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An innovative symptom monitoring tool for people with advanced lung cancer: a pilot demonstration.

D. Cella, D. Eton, S. Yount, 2007, The journal of supportive oncology.

DIAGNOSIS LUNG Treatment of Stage IV Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

M. Socinski, L. Sequist, S. Gettinger, 2013 .

Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer

T. Hensing, T. Karrison, R. Brisson, 2017, Oncotarget.

Should health-related quality of life be measured in cancer symptom management clinical trials? Lessons learned using the functional assessment of cancer therapy.

J. Cashy, D. Cella, S. Yount, 2007, Journal of the National Cancer Institute. Monographs.

Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC)

C. Obasaju, E. Hart, T. Hensing, 2008 .

Duration of therapy in advanced, metastatic non-small-cell lung cancer.

M. Socinski, T. Hensing, M. Baggstrom, 2003, Clinical advances in hematology & oncology : H&O.

Germline mutations in high penetrance genes are associated with worse clinical outcomes in patients with non–small cell lung cancer

Jianfeng Xu, K. Mangold, T. Hensing, 2022, JTCVS open.

Molecular pathways and therapeutic targets in lung cancer

Ravi Salgia, Raphael Bueno, R. Bueno, 2014, Oncotarget.

Treatment of Stage IV Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer , 3 rd ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

M. Socinski, L. Sequist, S. Gettinger, 2013 .

Nanoscale cellular changes in field carcinogenesis detected by partial wave spectroscopy.

Vadim Backman, Hariharan Subramanian, Prabhakar Pradhan, 2009, Cancer research.

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

C. Rudin, P. Hammerman, R. Govindan, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization.

R. Salgia, T. Hensing, R. Batra, 2014, Advances in experimental medicine and biology.

Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.

J. Jett, F. Khuri, H. Choy, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II Study of Gemcitabine and Exisulind as Second-Line Therapy in Patients with Advanced Non–small Cell Lung Cancer

T. Hensing, KyungMann Kim, J. Schiller, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Indications for Lymphatic Mapping and Sentinel Lymphadenectomy in Patients with Thin Melanoma (Breslow Thickness ≤1.0 mm)

T. Hensing, K. Stitzenberg, N. Thomas, 2004, Annals of Surgical Oncology.

The Chicago Thoracic Oncology Database Consortium: A Multisite Database Initiative

R. Salgia, T. Hensing, G. Carey, 2016, Cureus.

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.

M. Ladanyi, M. Zauderer, R. Yelensky, 2016, The oncologist.

A Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-small Cell Lung Cancer

D. Beer, Guoan Chen, T. Hensing, 2018, EBioMedicine.

Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation

Heber MacMahon, Ravi Salgia, Everett E. Vokes, 2016, Oncotarget.

Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database

Eneida A. Mendonça, Ravi Salgia, Rifat Hasina, 2011, Journal of Clinical Bioinformatics.

Third-Generation Chemotherapy Agents in the Treatment of Advanced Non-small Cell Lung Cancer: A Meta-Analysis

M. Socinski, C. Poole, T. Hensing, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck

T. Hensing, M. Bhayani, N. Campbell, 2016, Expert review of anticancer therapy.

Personalized treatment of lung cancer.

M. Maitland, R. Salgia, T. Hensing, 2011, Seminars in oncology.

A Multicenter Phase II Trial of Carboplatin and Cetuximab for Treatment of Advanced Nonsmall Cell Lung Cancer

M. Socinski, T. Hensing, T. Stinchcombe, 2009, Cancer investigation.

Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC

M. Knopp, T. Hensing, E. Vokes, 2021, JTO clinical and research reports.

A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer

M. Socinski, J. Beaumont, A. Peterman, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age (cid:1) 70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer

M. Socinski, J. Beaumont, A. Peterman, 2011 .

Outpatient advance care planning for patients with metastatic cancer: a pilot quality improvement initiative.

A. Robicsek, T. Hensing, J. Obel, 2014, Journal of palliative medicine.

Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer

N. Hanna, D. Gandara, R. Salgia, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review.

R. Salgia, T. Hensing, Kevin Wood, 2016, JAMA oncology.

Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung

T. Hensing, K. Shirai, G. Simon, 2014, Oncoscience.

The Feasibility of Adjuvant Carboplatin and Docetaxel in Patients with Curatively Resected Non-small Cell Lung Cancer

M. Socinski, F. Detterbeck, T. Hensing, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Buccal microRNA dysregulation in lung field carcinogenesis: Gender-specific implications

V. Backman, T. Hensing, H. Fernando, 2014, International journal of oncology.

A brief symptom index for advanced lung cancer.

A. Abernethy, J. Beaumont, D. Cella, 2012, Clinical lung cancer.

A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer.

M. Socinski, J. Beaumont, A. Peterman, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Optical detection of buccal epithelial nanoarchitectural alterations in patients harboring lung cancer: implications for screening.

Vadim Backman, Hariharan Subramanian, Prabhakar Pradhan, 2010, Cancer research.

Clinical evaluation and staging of patients who have lung cancer.

T. Hensing, 2005, Hematology/oncology clinics of North America.

Compassionate use experience with gefitinib in poor performance (PS) patients with advanced non-small-cell lung cancer (NSCLC) treated in an expanded access program (EAP).

R. Govindan, A. Wozniak, T. Hensing, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of induction therapy in the management of resectable non-small cell lung cancer.

M. Socinski, F. Detterbeck, T. Hensing, 2000, Cancer control : journal of the Moffitt Cancer Center.

Combined-modality therapy in the nonsurgical management of unresectable stage III non-small cell lung cancer.

M. Socinski, T. Hensing, 1999, Current opinion in pulmonary medicine.

Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer.

M. Socinski, M. Schell, T. Hensing, 2005, Lung cancer.

Clinical Applications of Proton MR Spectroscopy in Oncology

Mauricio Castillo, J. Keith Smith, Lester Kwock, 2002, Technology in cancer research & treatment.

A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer.

M. Socinski, T. Hensing, B. Qaqish, 2005, Lung cancer.

The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel

M. Socinski, A. Peterman, M. Schell, 2003, Cancer.

Pemetrexed and carboplatin plus bevacizumab for advanced non-squamous non-small cell lung cancer (NSCLC): Preliminary results

E. Hart, T. Hensing, J. Patel, 2007 .

Prevalence of Poor Performance Status in Lung Cancer Patients: Implications for Research

J. Cashy, D. Cella, T. Hensing, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non–Small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story

T. Hensing, J. Kolesar, A. Argiris, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Nanocytology for field carcinogenesis detection: novel paradigm for lung cancer risk stratification.

V. Backman, T. Hensing, H. Roy, 2011, Future oncology.

Optical detection of buccal epithelial nanoarchitectural alterations in patients harboring lung cancer: implications for screening.

V. Backman, H. Pass, W. Rom, 2010, Cancer research.

MA15.07 Molecular Determinants of Lack of Tumor Immune Infiltration in NSCLC

Yusuke Nakamura, T. Hensing, E. Vokes, 2017 .

Clinical benefit with compassionate use gefitinib in a subset of non-small-cell lung cancer (NSCLC) patients with the bronchoalveolar (BAC) subtype treated during an expanded access program (EAP).

R. Govindan, A. Wozniak, T. Hensing, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dermatologic infections complicating epidermal growth factor receptor inhibitor (EGFRI) therapy in lung cancer patients.

M. Lacouture, T. Hensing, M. Agulnik, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

M. Socinski, S. Gettinger, T. Hensing, 2013, Chest.